These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 10477166

  • 1. A double-blind randomized study comparing intramuscular (i.m.) granisetron with i.m. granisetron plus dexamethasone in the prevention of delayed emesis induced by cisplatin. The Italian Multicenter Study Group.
    Anticancer Drugs; 1999 Jun; 10(5):465-70. PubMed ID: 10477166
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
    Chiou TJ, Tzeng WF, Wang WS, Yen CC, Fan FS, Liu JH, Chen PM.
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
    [Abstract] [Full Text] [Related]

  • 3. Comparative study of low-dose oral granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone in prevention of nausea and vomiting induced by CHOP-therapy in young patients with non-Hodgkin's lymphoma.
    Numbenjapon T, Sriswasdi C, Mongkonsritragoon W, Leelasiri A, Prayoonwiwat W.
    J Med Assoc Thai; 2002 Nov; 85(11):1156-63. PubMed ID: 12546311
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.
    Van Belle S, Lichinitser MR, Navari RM, Garin AM, Decramer ML, Riviere A, Thant M, Brestan E, Bui B, Eldridge K, De Smet M, Michiels N, Reinhardt RR, Carides AD, Evans JK, Gertz BJ.
    Cancer; 2002 Jun 01; 94(11):3032-41. PubMed ID: 12115394
    [Abstract] [Full Text] [Related]

  • 7. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
    de Wit R, Herrstedt J, Rapoport B, Carides AD, Guoguang-Ma J, Elmer M, Schmidt C, Evans JK, Horgan KJ.
    Eur J Cancer; 2004 Feb 01; 40(3):403-10. PubMed ID: 14746859
    [Abstract] [Full Text] [Related]

  • 8. [Combination effect of granisetron plus corticosteroid for prevention of cisplatin-induced emesis: a cross-over study comparing methylprednisolone and dexamethasone].
    Tanaka K, Sekine M, Serikawa T, Sanada H, Shichiri K, Fujimori R.
    Gan To Kagaku Ryoho; 1998 May 01; 25(6):907-13. PubMed ID: 9617330
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of droperidol in the prevention of cisplatin-induced delayed emesis: a double-blind, randomised parallel study.
    Minegishi Y, Ohmatsu H, Miyamoto T, Niho S, Goto K, Kubota K, Kakinuma R, Kudoh S, Nishiwaki Y.
    Eur J Cancer; 2004 May 01; 40(8):1188-92. PubMed ID: 15110882
    [Abstract] [Full Text] [Related]

  • 10. A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy.
    Ettinger DS, Eisenberg PD, Fitts D, Friedman C, Wilson-Lynch K, Yocom K.
    Cancer; 1996 Jul 01; 78(1):144-51. PubMed ID: 8646710
    [Abstract] [Full Text] [Related]

  • 11. A randomized, double-blind, parallel, comparative study to evaluate the efficacy and safety of ramosetron plus dexamethasone injection for the prevention of acute chemotherapy-induced nausea and vomiting.
    Ho CL, Su WC, Hsieh RK, Lin ZZ, Chao TY.
    Jpn J Clin Oncol; 2010 Apr 01; 40(4):294-301. PubMed ID: 20026457
    [Abstract] [Full Text] [Related]

  • 12. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
    Chawla SP, Grunberg SM, Gralla RJ, Hesketh PJ, Rittenberg C, Elmer ME, Schmidt C, Taylor A, Carides AD, Evans JK, Horgan KJ.
    Cancer; 2003 May 01; 97(9):2290-300. PubMed ID: 12712486
    [Abstract] [Full Text] [Related]

  • 13. [A comparative study of the effects of granisetron alone and a combination of granisetron plus steroids on CDDP-based combination chemotherapy-induced emesis--outcomes of a multicenter randomized comparative study using the central registration method. Nara Medical University Kytril Study Group].
    Ozono S, Okajima E, Hirao YK, Natsume O, Kaneko Y, Ohara S, Tabata S, Watanabe S, Aoyama H, Sasaki K, Matsuki H, Takashima K, Maruyama Y, Yoshikawa M, Yamada K, Momose H, Hiramatsu T, Hayashi Y, Babaya K, Shiomi T.
    Gan To Kagaku Ryoho; 1997 Feb 01; 24(3):349-56. PubMed ID: 9051139
    [Abstract] [Full Text] [Related]

  • 14. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone.
    Campos D, Pereira JR, Reinhardt RR, Carracedo C, Poli S, Vogel C, Martinez-Cedillo J, Erazo A, Wittreich J, Eriksson LO, Carides AD, Gertz BJ.
    J Clin Oncol; 2001 Mar 15; 19(6):1759-67. PubMed ID: 11251007
    [Abstract] [Full Text] [Related]

  • 15. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
    Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F, Aprepitant Protocol 054 Study Group.
    Cancer; 2003 Jun 15; 97(12):3090-8. PubMed ID: 12784346
    [Abstract] [Full Text] [Related]

  • 16. Comparative crossover trial of two intravenous doses of granisetron (1 mg vs 3 mg) + dexamethasone in the prevention of acute cis-platinum-induced emesis.
    Martoni A, Piana E, Strocchi E, Angelelli B, Guaraldi M, Zamagni C, Camaggi CM, Pannuti F.
    Anticancer Res; 1998 Jun 15; 18(4B):2799-803. PubMed ID: 9713464
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of oral granisetron versus oral prochlorperazine in preventing nausea and emesis in patients receiving moderately emetogenic chemotherapy.
    Burris H, Hesketh P, Cohn J, Moriconi W, Ryan T, Friedman C, Fitts D.
    Cancer J Sci Am; 1996 Jun 15; 2(2):85-90. PubMed ID: 9166505
    [Abstract] [Full Text] [Related]

  • 18. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials.
    Warr DG, Grunberg SM, Gralla RJ, Hesketh PJ, Roila F, Wit Rd, Carides AD, Taylor A, Evans JK, Horgan KJ.
    Eur J Cancer; 2005 Jun 15; 41(9):1278-85. PubMed ID: 15939263
    [Abstract] [Full Text] [Related]

  • 19. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group.
    Navari RM, Reinhardt RR, Gralla RJ, Kris MG, Hesketh PJ, Khojasteh A, Kindler H, Grote TH, Pendergrass K, Grunberg SM, Carides AD, Gertz BJ.
    N Engl J Med; 1999 Jan 21; 340(3):190-5. PubMed ID: 9917226
    [Abstract] [Full Text] [Related]

  • 20. Single-agent oral granisetron for the prevention of acute cisplatin-induced emesis: a double-blind, randomized comparison with granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone.
    Heron JF.
    Semin Oncol; 1995 Aug 21; 22(4 Suppl 10):24-30. PubMed ID: 7570051
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.